Bulletin of Experimental Biology and Medicine

, Volume 162, Issue 4, pp 515–519 | Cite as

The Use of Human Liver Cell Model and Cytochrome P450 Substrate—Inhibitor Panel for Studies of Dasatinib and Warfarin Interactions

  • A. A. Zakharyants
  • O. A. Burmistrova
  • A. A. Poloznikov
METHODS
  • 97 Downloads

The possibility of interactions between warfarin and dasatinib and their interactions with other drugs metabolized by cytochrome P450 isoform CYP3A4 was demonstrated using a previously created cytochrome P450 substrate—inhibitor panel for preclinical in vitro studies of drug biotransformation on a 3D histotypical microfluidic cell model of human liver (liver-on-a-chip technology). Dasatinib and warfarin are inhibitors of CYP2C19 isoform and hence, can interfere the drugs metabolized by this isoform. Our findings are in line with the data obtained on primary culture of human hepatocytes and suggest that the model can be used in preclinical in vitro studies of drugs.

Key Words

biotransformation microbioreactor cell model of the liver drug interactions 

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. 1.
    Aleksandrova AV, Burmistrova OA, Fomicheva KA, Sakharov DA. Maintenance of high cytochrome P450 expression in HepaRG cell spheroids in DMSO-free medium. Bull. Exp. Biol. Med. 2016;161(1):120-124.CrossRefPubMedGoogle Scholar
  2. 2.
    Alexandrova AV, Pul’kova NV, Sakharov DA. Complex approach to xenobiotics hepatotoxicity testing using a microfluidic system. Bull. Exp. Biol. Med. 2016;161(1):50-53.CrossRefPubMedGoogle Scholar
  3. 3.
    Au SH, Chamberlain MD, Mahesh S, Sefton MV, Wheeler AR. Hepatic organoids for microfluidic drug screening. Lab Chip. 2014;14(17):3290-3299.CrossRefPubMedGoogle Scholar
  4. 4.
    Bogaards JJ, Bertrand M, Jackson P, Oudshoorn MJ, Weaver RJ, van Bladeren PJ, Walther B. Determining the best animal model for human cytochrome P450 activities: acomparison of mouse, rat, rabbit, dog, micropig, monkey and man. Xenobiotica. 2000;30(12):1131-1152.CrossRefPubMedGoogle Scholar
  5. 5.
    Cheung C, Gonzalez FJ. Humanized mouse lines and their application for prediction of human drug metabolism and toxicological risk assessment. J. Pharmacol. Exp. Ther. 2008;327(2): 288-299.CrossRefPubMedPubMedCentralGoogle Scholar
  6. 6.
    Duckett DR, Cameron MD. Metabolism considerations for kinase inhibitors in cancer treatment. Expert Opin. Drug Metab. Toxicol. 2010;6(10):1175-1193.CrossRefPubMedPubMedCentralGoogle Scholar
  7. 7.
    Flockhart DA, O’Kane D, Williams MS, Watson MS, Flockhart DA, Gage B, Gandolfi R, King R, Lyon E, Nussbaum R, O’Kane D, Schulman K, Veenstra D, Williams MS, Watson MS; ACMG Working Group on Pharmacogenetic Testing of CYP2C9, VKORC1 Alleles for Warfarin Use. Pharmacogenetic testing of CYP2C9 and VKORC1 alleles for warfarin. Genet Med. 2008;10(2):139-150.CrossRefPubMedGoogle Scholar
  8. 8.
    Haouala A, Widmer N, Duchosal MA, Montemurro M, Buclin T, Decosterd LA. Drug interactions with the tyrosine kinase inhibitors imatinib, dasatinib, and nilotinib. Blood. 2011; 117(8):e75-e87.CrossRefPubMedGoogle Scholar
  9. 9.
    Khetani SR, Berger DR, Ballinger KR, Davidson MD, Lin C, Ware BR. Microengineered liver tissues for drug testing. J. Lab. Autom. 2015;20(3):216-250.CrossRefPubMedGoogle Scholar
  10. 10.
    Langley G, Austin CP, Balapure AK, Birnbaum LS, Bucher JR, Fentem J, Fitzpatrick SC, Fowle JR 3rd, Kavlock RJ, Kitano H, Lidbury BA, Muotri AR, Peng SQ, Sakharov D, Seidle T, Trez T, Tonevitsky A, van de Stolpe A, Whelan M, Willett C. Lessons from toxicology: developing a 21st-century paradigm for medical research. Environ. Health Perspect. 2015;123(11):A268-A272.CrossRefGoogle Scholar
  11. 11.
    Maltseva DV, Khaustova NA, Fedotov NN, Matveeva EO, Lebedev AE, Shkurnikov MU, Galatenko VV, Schumacher U, Tonevitsky AG. High-throughput identification of reference genes for research and clinical RT-qPCR analysis of breast cancer samples. J. Clin. Bioinforma. 2013;3(1):13. doi:  10.1186/2043-9113-3-13.CrossRefPubMedPubMedCentralGoogle Scholar
  12. 12.
    Martignoni M, Groothuis GM, de Kanter R. Species differences between mouse, rat, dog, monkey and human CYP-mediated drug metabolism, inhibition and induction. Expert Opin. Drug Metab. Toxicol. 2006;2(6):875-894.CrossRefPubMedGoogle Scholar
  13. 13.
    Materne EM, Ramme AP, Terrasso AP, Serra M, Alves PM, Brito C, Sakharov DA, Tonevitsky AG, Lauster R, Marx U. A multi-organ chip co-culture of neurospheres and liver equivalents for long-term substance testing. J. Biotechnol. 2015;205:36-46.CrossRefPubMedGoogle Scholar
  14. 14.
    Okin D, Medzhitov R. The effect of sustained inflammation on hepatic mevalonate pathway results in hyperglycemia. Cell. 2016;165(2):343-356.CrossRefPubMedGoogle Scholar
  15. 15.
    Shirayama T, Shiraishi H, Kuroyanagi A, Hamaoka T, Imai M, Kojima A. Interaction between warfarin and proton pump inhibitors. Int. J. Clin. Med. 2014;5(14):836-843. doi:  10.4236/ijcm.2014.514112.CrossRefGoogle Scholar

Copyright information

© Springer Science+Business Media New York 2017

Authors and Affiliations

  • A. A. Zakharyants
    • 1
  • O. A. Burmistrova
    • 1
  • A. A. Poloznikov
    • 1
  1. 1.BioClinicum CenterMoscowRussia

Personalised recommendations